Which peptides are studied in relation to chronotype?
A research-catalogue summary of the peptide and peptide-adjacent compounds examined alongside chronotype, circadian timing and sleep-wake phase, with the models and mechanisms each study used.
The short answer is that no peptide has been established as a chronotype determinant in human research. What the indexed literature contains is a set of peptide and peptide-adjacent compounds studied in relation to circadian timing, sleep-wake phase and chronotype-adjacent phenotypes, mostly in animal or in vitro models, plus a larger body of non-peptide work on chronotype itself. The formal term for the trait under study is chronotype, sometimes written as circadian preference or diurnal preference; it is a behavioural phenotype, not a molecular entity, and it has no sequence, formula or molecular weight. The compounds below are the ones the evidence block actually names or implies, and each is reported with the model it was studied in.
The pathway family that most of this work centres on is the circadian clock machinery — the transcriptional-translational feedback loops operating through CLOCK, BMAL1, PER and CRY — together with the melatonin synthesis and signalling axis that reports clock phase to the rest of the body.
Research Studies
Melatonin and dim-light melatonin onset in evening-type adolescents
Melatonin is the indoleamine output signal of the pineal clock, and its onset under dim light is the standard phase marker used to classify chronotype in laboratory settings. A registered trial in adolescents with ADHD, insomnia and evening chronotype is evaluating cognitive behavioural therapy for insomnia with or without bright light therapy, on the basis that circadian delay and insomnia co-occur in this population and may affect daytime functioning and clinical outcomes [2]. The trial does not test a peptide as an intervention; it uses light as the phase-shifting input and treats the melatonin rhythm as the readout of interest.
Exercise timing and glycaemic handling in prediabetic adults with extreme chronotype
A registered crossover trial is comparing no exercise, morning exercise and evening exercise within the same participants with prediabetes and an extreme natural body clock, with at least 14 days between test days, to determine whether the timing of a single session changes how the body handles sugar [1]. No peptide is administered. The relevance to peptide research is indirect: exercise timing is used as a probe of clock-controlled metabolic output, and any downstream peptide or hormonal mediator would be measured rather than dosed.
Morning versus afternoon training in athletes and active adults
A structured narrative review synthesised evidence on morning versus afternoon or evening training in athletes and physically active adults, integrating performance outcomes with internal load, autonomic recovery, sleep interaction and downstream physiological stress [3]. Acute evidence generally supported superior late-afternoon or early-evening performance, particularly for neuromuscular tasks, whereas chronic training studies did not indicate a universal optimal training time [3]. This is a physiological and performance literature, not a peptide literature, and it is included here because it defines the timing variable that peptide-focused work would need to control for.
Nocturia, circadian rhythm disturbance and pelvic floor symptoms in women
A registered study is examining how nocturia affects pelvic floor symptoms, sleep parameters and quality of life in women with urinary incontinence, on the premise that nocturia can arise from sleep disorders and circadian rhythm disturbances and that chronotype varies between individuals [4]. The study population is women with urinary incontinence. No peptide intervention is described.
Metabolic signatures of sleep health and stroke risk
A prospective cohort study in 200,729 UK Biobank participants investigated whether a nuclear magnetic resonance-derived metabolic signature mediates the association between healthy sleep and lower stroke risk [5]. The analytes in question are small-molecule and lipoprotein metabolites rather than peptides, and the finding is reported here as context for how sleep phenotypes are linked to measurable circulating markers.
Where the peptide evidence is animal-only or in vitro
The evidence block does not supply a named peptide studied directly against chronotype in a human trial. Claims that a specific peptide shifts chronotype, advances sleep phase or treats circadian delay in humans are not supported by the sources available here and are therefore not made on this page. Where peptide work exists in the wider literature, it should be assessed on its own model — cell culture, rodent or human — and the model stated explicitly.
Comparison of the models used across the cited work
| Study | Population or model | Compound or input | Outcome domain |
|---|---|---|---|
| [1] | Adults with prediabetes and extreme chronotype | Exercise timing (no peptide) | Glycaemic handling |
| [2] | Adolescents with ADHD, insomnia, evening chronotype | CBT-I with or without bright light | Insomnia and circadian delay |
| [3] | Athletes and physically active adults | Training time of day | Performance, recovery, biological cost |
| [4] | Women with urinary incontinence | Nocturia observation | Sleep parameters, quality of life |
| [5] | 200,729 UK Biobank participants | NMR metabolic signature | Stroke risk mediation |
Identifiers and what is absent from the record
Chronotype itself carries no CAS number, sequence or molecular weight, because it is a behavioural classification rather than a substance. None of the cited sources provides a peptide sequence, formula or molecular weight in connection with chronotype, and none reports a human dose of any peptide for a circadian indication. Researchers designing work in this area should treat the cited trials as methodological templates for timing-based designs rather than as evidence for any particular compound.
If you are reading this for personal health reasons
The materials described on this page are sold for laboratory research only, and we do not provide dosing, medical or treatment guidance of any kind. Nothing here is a recommendation to use any compound, and no statement on this page should be read as a promise of an outcome. Anyone considering a compound for themselves should speak to a licensed clinician.
Sources
- [1] Exercise, Chronotype, and Prediabetes — https://clinicaltrials.gov/study/NCT07389005
- [2] Efficacy of Cognitive Behavioural Therapy for Insomnia and Bright Light Therapy in Adolescents With ADHD, Insomnia, and Evening Chronotype — https://clinicaltrials.gov/study/NCT07767617
- [3] Exercise Timing in Sport: Molecular and Physiological Mechanisms Linking Performance, Recovery, and Biological Cost — https://europepmc.org/article/PMC/PMC13206971
- [4] Examination of the Effect of Nocturia on Pelvic Floor Symptoms, Sleep Parameters and Quality of Life in Women With Urinary Incontinence — https://clinicaltrials.gov/study/NCT06866834
- [5] Metabolic signatures of sleep health and stroke risk: A prospective cohort study with mediation analysis — https://pubmed.ncbi.nlm.nih.gov/42660766/